D ominant optic atrophy (DOA; Online Mendelian Inheritance in Man [OMIM] 165500) is one of the most common inherited optic neuropathies encountered in neuro-ophthalmological practice, and approximately 60% of affected individuals will harbor a pathogenic mutation in the OPA1 gene (3q28-q29).
1,2 DOA was thought to have a relatively limited ocular phenotype, with most patients experiencing an insidious onset of central visual failure starting in early childhood due to the focal loss of RGCs within the papillo-macular bundle. 3 However, we and others have recently described DOA pedigrees where the visual loss also segregated with more severe neuromuscular deficits such as progressive external ophthalmoplegia (PEO), deafness, ataxia, myopathy, and peripheral neuropathy. 4 -6 Interestingly, skeletal muscle biopsies were available from some of the affected family members, and these showed unequivocal features of mitochondrial dysfunction with a mosaic pattern of COX-deficient muscle fibers and the presence of multiple mtDNA deletions on long-range polymerase chain reaction (PCR). 4, 5 The Opa1 protein is part of the large, dynamin GTPase family of mechanoenzymes and is located within the inner mitochondrial membrane, 7 providing intriguing causal links to the hitherto undescribed muscle changes in these "DOA plus" pedigrees. The underlying pathophysiology in DOA remains largely unexplained, and the accumulation of secondary mtDNA abnormalities could represent an important mechanism that triggers the downstream events leading to cellular dysfunction and loss of function, especially within RGCs. Basic research in DOA has been severely restricted by the lack of affected human specimens and for this reason, we have recently developed an Opa1 mouse model to explore these fundamental molecular mechanisms in greater detail. 8 To determine the role of COX deficiency and secondary mtDNA deletions in the RGC loss that characterizes DOA, we carried out a physiological, biochemical, and molecular genetic study in our mutant Opa1 mice.
MATERIALS AND METHODS

Opa1 Mice
We have established a mouse model of DOA (B6;C3-Opa1 Q285STOP ) with a heterozygous nonsense mutation in exon 8 (c.1051CϾT) of the Opa1 gene, which results in the introduction of a stop codon (Q285STOP) and a 50% reduction in the expression of the Opa1 protein. 8 Breeding, maintenance, and euthanatization were in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Homozygous mutant mice (Opa1 Ϫ/Ϫ ) died in utero during embryogenesis but heterozygous Opa1 ϩ/Ϫ mice faithfully replicated the human phenotype, exhibiting a slowly progressive optic neuropathy and demonstrating objective reduction in visual function on psychophysical testing.
Visual Assessment
Visual function was formally assessed with a rotating optokinetic (OKN) drum using high resolution 2°and low resolution 8°gratings, which correspond to 0.25 and 0.0625 cycles/degree respectively, and OKN responses were recorded using a validated protocol. 9, 10 We have previously reported visual data on 6-and 12-month-old Opa1 ϩ/Ϫ mice 8 and in this study, further visual assessment was performed by one investigator (VJD) on an older cohort of heterozygous mutant Opa1 ϩ/Ϫ mice (n ϭ 14 at 13 months and n ϭ 12 at 18 months) and an age-and sex-matched group of C57Bl/6 wild-type mice (n ϭ 14 at 13 months and n ϭ 12 at 18 months). OKN data for both wild-type and mutant mice was collected on the same day, under the same experimental conditions.
Neurologic Evaluation
The primary SHIRPA examination is a comprehensive screening technique used to define abnormal mouse phenotypes in disease models.
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It consists of 37 separate general health and neurologic measures and provides quantitative information on muscle, cerebellar, sensory, neuropsychiatric, and autonomic functions (http://www.har.mrc.ac.uk/ services/phenotyping/neurology/shirpa.html). Using this assessment tool, our heterozygous mutant Opa1 ϩ/Ϫ mice did not show any gross neuromuscular deficits at age 6 months and had a normal lifespan, similar to their Opa1 ϩ/ϩ control littermates. 8 In this study, 14 Opa1 ϩ/Ϫ mice and 14 age-and sex-matched C57Bl/6 controls were reevaluated at age 13 months with the primary SHIRPA protocol. This included tests of muscle tone, power and coordination, as well as hearing using the MRC standard click box (90 dB and 18 -20 Hz).
Histochemistry
The gastrocnemius muscle was harvested from the leg area and both eyes were enucleated from the following mice: 2-month-old Opa1 ϩ/ϩ (n ϭ 3), 2-month-old Opa1Ϯ (n ϭ 3), 11-month-old Opa1 ϩ/ϩ (n ϭ 3), and 11-month-old Opa1 ϩ/Ϫ (n ϭ 3). The muscle and eye specimens were immediately frozen in a melting isopentane bath (-150°C) and stored at -80°C. Serial sections were subsequently cut and mounted onto glass slides using a cryostat (Microm HM560; Thermo Fisher, Walldorf, Germany), at 20 m thickness for muscle and 12 m thickness for the eye specimens. The tissue sections were then stained using standard protocols for hematoxylin and eosin (H&E), cytochrome c oxidase (COX), succinate dehydrogenase (SDH) and dual COX-SDH. 12, 13 Myofibrillar adenosine triphosphatase (ATPase) staining, with a pre-incubation pH of 4.3, was also performed on serial muscle sections.
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DNA Extraction
Muscle homogenate DNA was extracted using a hard tissue kit (Nucleon; Tepnel, Manchester, UK) but given the small quantities involved, an alternative method was devised to obtain an adequate yield of RGC DNA. Opa1 mouse eyes were serially sectioned onto membrane slides and stained with dual COX-SDH to localize the RGC layer and cell bodies (Fig. 1A) . RGC blocks (100 m ϫ 500 m) were then cut using a laser dissecting microscope (LMD 6000; Leica Microsystems, Wetzlar, Germany) and collected into a 1.5 mL microcentrifuge cap (Figs. 1B, 1C). A total of 200 RGC blocks were pooled together for each mouse, with 10 RGC blocks dissected from 10 serial sections of both right and left eyes. The dissection block included both the RGC cell bodies and the proximal axonal segment within the retinal nerve fiber layer. DNA extraction was performed using a purification kit (QIAamp DNA Micro Kit; Qiagen, Crawley, UK) and eluted in 20 L of TE buffer.
Long-range PCR Assay
Six primer pairs, available on request, were specifically designed to amplify overlapping mtDNA regions and identify possible rearrangements, especially in the mutational hotspots along the major arc of the mitochondrial genome and involving MTND4 ( Fig. 2A) . 16 A long-range kit (Roche Expand Long-Range Kit; Roche Applied Science, Indianapolis, IN) was used with the manufacturer's recommended cycling procedures and the PCR products were electrophoresed in a 0.7% agarose gel at 40 V for 3 hours.
Quantitative PCR Assay
Relative copy number was determined in homogenate muscle DNA using a well-established iQ SYBR Green protocol on the real-time PCR detection system (MyiQ; BioRad Laboratories, Hercules, CA), with MTND5 as the mtDNA reference gene and GAPDH as the nuclear DNA (nDNA) reference gene. 17, 18 Both assays were optimized and confirmed to be linear over an appropriate concentration range, and all measurements were done in triplicate. The mtDNA/nDNA ratio was derived from the difference in threshold cycle value (⌬Ct) between MTND5 and GAPDH, using the 2 Ϫ⌬Ct method.
Statistical Analysis
Statistical analyses were performed using statistical software (SPSS v. 15; SPSS, Chicago, IL). An independent sample t-test and two-way ANOVA were used to compare the OKN responses, primary SHIRPA scores and mtDNA/nDNA ratio between mutant and wild-type mice, as required. The error bars in the figures provided represent the standard error of the mean (SEM). 
RESULTS
Visual Function
Slit lamp and dilated fundal examinations did not reveal any gross ocular pathology such as anterior segment dysgenesis, cataracts, or retinal pigmentary changes in all Opa1 mice studied. In this study, 13-month-old Opa1 ϩ/Ϫ mice displayed statistically significant decreased mean tracking frequency at both 2°and 8°gratings (P Ͻ 0.001) compared to wild-type C57Bl/6 mice (main effect of genotype, P Ͻ 0.001; main effect of grating, P ϭ 0.435; grating by genotype interaction, P ϭ 0.461; Fig. 3A) . At age 18 months, the difference between mutant and control groups was significant for the 8°grating (P ϭ 0.003) but not for the 2°grating (P ϭ 0.082; Fig. 3B ). There was also a statistically significant reduction in OKN responses between the 2°and 8°gratings at age 18 months (main effect of genotype, P ϭ 0.325; main effect of grating, P ϭ 0.001; grating by genotype interaction, P ϭ 0.880). The ratio of mean tracking frequency (C57Bl/6 vs. Opa1 ϩ/Ϫ ) was 1.53 for the 2°grating and 1.70 for the 8°grating at age 13 months, and 1.05 for the 2°grating and 1.06 for the 8°grating at age 18 months.
Neurologic Phenotype
The primary SHIRPA neurologic examination did not reveal any functional neurologic deficits in the Opa1 ϩ/Ϫ mice at age 13 months. No gait abnormalities or tremor were present at resting level and there was no statistically significant difference in limb tone, grip strength, and muscle coordination between mutant and wild-type mice. Compared to wild-type C57Bl/6 controls, Opa1 ϩ/Ϫ mice had increased transfer arousal and locomotor activity scores, indicating that they were possibly more anxious and fearful in novel environments (P Ͻ 0.05). All the Opa1 ϩ/Ϫ mice tested had normal hearing test results with the MRC standard click box.
Histology and mtDNA Analysis
In the 12 Opa1 mice that were studied, H&E and myofibrillar ATPase staining showed normal muscle fiber morphology, with no inflammatory or neuropathic changes such as muscle fiber necrosis, regeneration, or fiber type grouping. There were no ragged red fibers (RRFs) on SDH staining and no COX deficient fibers were identified, with an average sampling of 3793 muscle fibers for each mouse (SD, 1049; range, 1690 -5302; Fig. 4) . Similarly, we found no evidence of COX-deficient regions within the RGC layer of both the 2-month and 11-month-old Opa1 ϩ/ϩ and Opa1 ϩ/Ϫ mice (Fig. 5) . The longrange PCR assay using all 6 primer pairs only amplified full mtDNA fragments with no evidence of smaller amplicons in both control and mutant groups (Fig. 2B) . There was no statistically significant difference in mtDNA/nNDA ratio in muscle from Opa1 ϩ/Ϫ (mean, 16.58; SD, 2.71; n ϭ 6) and Opa1 ϩ/ϩ mice (mean, 15.17; SD, 4.51; n ϭ 6; P ϭ 0.795; Fig. 6 ). 
FIGURE 3.
Performance on the optokinetic visual screening test expressed as the mean frequency of tracking a moving 2°and 8°grating for 2 minutes at (A) 13 months: Opa1 ϩ/Ϫ mice (n ϭ 14) and C57Bl/6 controls (n ϭ 14); (B) 18 months: Opa1 ϩ/Ϫ mice (n ϭ 12) and C57B6 controls (n ϭ 12). **P Ͻ 0.001; *P ϭ 0.003; NS, non-significant at P ϭ 0.082.
DISCUSSION
We previously reported a significant reduction in OKN responses in our heterozygous mutant Opa1 ϩ/Ϫ mice age 12 months compared to their littermate controls. In this report, we extended our observations to a more aged colony and further confirm that the pathogenic variant in exon 8 (c.1051CϾT) of the Opa1 gene leads to optic nerve dysfunction in our heterozygous mutant mice. The optic neuropathy is relatively mild, as none of the Opa1 ϩ/Ϫ mice completely failed to track the gratings, consistent with the better visual prognosis in DOA compared to other inherited optic neuropathies such as Leber hereditary optic neuropathy (LHON; OMIM 535000). 3 There was a statistically significant reduction in mean tracking frequency between Opa1 ϩ/Ϫ mice and C57Bl/6 controls for both 2°and 8°gratings at age 13 months, but the difference was only significant for the 8°grating at age 18 months. The most likely explanation is a loss of visual acuity occurring with age for the C57Bl/6 mice, which reduced the difference between mutant and wild-type mice at the higher resolution 2°grating but not at the lower resolution 8°grating. The OKN ratios at age 13 and age 18 months also suggest that visual acuity does not deteriorate further with advancing age in our Opa1 ϩ/Ϫ mice, which is similar to the natural history of DOA in humans, where less than 50% of affected patients experience further, albeit gradual, deterioration in their visual function on long-term follow-up. 19 -21 A comprehensive histochemical analysis of muscle and eye specimens failed to demonstrate any COX deficient areas and no mtDNA deletions were identified using our long-range PCR assay. Quantitative analysis on homogenate muscle DNA also showed no evidence of significant mitochondrial depletion or proliferation in the Opa1 ϩ/Ϫ mice compared to Opa1 ϩ/ϩ controls. If the pathogenic Opa1 mutation induced these secondary mitochondrial changes, we would have expected these to be apparent in the 11-month-old Opa1Ϯ mice, an age group in which visual dysfunction had already developed. In addition, we previously showed with electron microscopy that significant morphologic changes were clearly visible by the age of 9 months within the optic nerve, with abnormally swollen and distorted RGC axons, and irregular areas of demyelination and myelin aggregates along the nerve fiber bundles. 8, 22 A limitation of our experimental procedures is the inability to visualize individual RGC cell bodies and axons due to their small size, and it is possible that isolated COX deficient RGCs were present that have been missed. However, long-range PCR is a very sensitive molecular technique because of its preferential amplification of smaller mtDNA species and yet, enriching for RGCs by laser microdissection did not reveal any mtDNA deletions. 23 Another possible argument is that COX deficient RGCs were present in the pre-clinical stages but these were then lost coincident with the onset of optic nerve dysfunction. Although we cannot absolutely exclude this scenario, it is somewhat unlikely given the consistent observations of viable COX-deficient neurons in brain biopsies from patients with neurodegenerative disorders such as Parkinson's disease, where COX-deficient neurons accumulate both with increasing age and progression of the disease process. 24, 25 Furthermore, previous retinal histologic analysis of our Opa1 ϩ/Ϫ mice did not show any significant reduction in total RGC count. 8 How can we then account for this apparent disparity between our Opa1 mouse model and the recent reports of COX deficiency and multiple mtDNA deletions in "DOA plus" pedigrees? We recently investigated a cohort of 21 patients with multi-systemic neuromuscular disorders, COX-deficient muscle fibers, and multiple mtDNA deletions. 26 Initial mutational screen for genes previously described in patients with multiple mtDNA deletions was negative: POLG1, POLG2, SLC25A4, and PEO1, but subsequent OPA1 gene sequencing identified pathogenic variants in three probands who also had visual failure; that is, 14% of our study cohort. Although the underlying mechanisms are unknown, this very interesting finding provides additional robust evidence that some OPA1 mutations do lead to the formation and clonal expansion of mtDNA deletions.
All the causative OPA1 mutations in these "DOA plus" families have so far been missense mutations with most, but not all of them, within the catalytic GTPase site of the protein. 4 -6 Although functional studies are lacking, it has been speculated that the more severe phenotype is the consequence of the mutant Opa1 protein exerting a dominant negative effect, and the more severe cellular dysfunction becomes apparent not only within RGCs, but also in other "at-risk mitochondrial" tissues such as extra-ocular muscles, skeletal muscle, and brain. 27 If this hypothesis is substantiated, it is perhaps not surprising that we failed to detect these abnormalities in our Opa1 mutant mice, where the pathology is limited to the optic nerve, that is, "pure DOA," with no evidence to suggest additional neurologic deficits such as muscle weakness, ataxia, or deafness, using the well-validated primary SHIRPA screen.
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The heterozygous exon 8 mutation (c.1051CϾT) in our Opa1 mice is also truncative (Q285STOP) and overall results in a 50% reduction in the expression of the Opa1 protein, thereby representing a haploinsufficiency, and not a dominant negative, disease model. We previously showed the following percentage decrease in Opa1 protein levels in a panel of postmitotic tissues harvested from Opa1 ϩ/Ϫ mice: retina (55%), brain (50%), skeletal muscle (80%), heart (55%), liver (80%), kidney (35%), and spleen (65%). 8 Although our results relate only to this specific mouse model, one could speculate that secondary mtDNA abnormalities do not contribute to optic nerve dysfunction among patients with truncative OPA1 mutations and a "pure DOA" phenotype. It is perhaps also premature to conclude that COX deficiency and multiple mtDNA deletions are a sine qua non for a more severe disease progression in DOA. Spinazzi and colleagues 28 have recently described a large, multi-generational pedigree where the optic atrophy segregated with mild myopathy and an axonal sensory-motor peripheral neuropathy. In contrast to previous "DOA plus" pedigrees, COX deficient muscle fibers and multiple mtDNA deletions were absent and a novel OPA1 deletion in the GTPase domain (c.1410_ 1443ϩ4del38) was identified that reduced the level of protein expression by half; that is, led to haploinsufficiency. Functional studies performed on fibroblast and myoblast cultures showed no demonstrable respiratory chain defects, in contrast to the common c.2708_2711delTTAG OPA1 deletion, which has been shown to inhibit mitochondrial oxidative phosphorylation in both in vitro fibroblast 29 and in vivo muscle assays. 30 However, the c.1410_1443ϩ4del38 mutation led to marked fragmentation of the mitochondrial network, an effect also seen with other OPA1 mutations 3 and in fibroblasts derived from our mouse model, 8 highlighting the additional important pro-fusion function of the Opa1 protein.
Opa1 is proving to be a multi-faceted protein with several crucial molecular roles relating to mtDNA replication, oxidative phosphorylation, maintenance of the mitochondrial network and apoptosis. The challenge ahead will be to unravel how OPA1 mutations actually lead to loss of function, not only in RGCs, but also in other post-mitotic tissues to explain the expanding clinical spectrum being documented in DOA families. In this respect another Opa1 mouse model with more severe neurologic deficits in addition to the optic neuropathy would provide invaluable insights into these molecular mechanisms and how they interact to cause disease. Understanding these key pathophysiological steps will hopefully lead to the development of effective neuroprotective strategies with clinical benefits to patients with DOA.
